Tocilizumab in COVID‐19 interstitial pneumonia

BACKGROUND: Published reports on tocilizumab in COVID‐19 pneumonitis show conflicting results due to weak designs or heterogeneity in critical methodological issues. METHODS: This open‐label trial, structured according to Simon's optimal design, aims to identify factors predicting which patient...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Intern Med
Prif Awduron: Pomponio, G., Ferrarini, A., Bonifazi, M., Moretti, M., Salvi, A., Giacometti, A., Tavio, M., Titolo, G., Morbidoni, L., Frausini, G., Onesta, M., Amico, D., Rocchi, M. L. B., Menzo, S., Zuccatosta, L., Mei, F., Menditto, V., Svegliati, S., Donati, A., D'Errico, M. M., Pavani, M., Gabrielli, A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2021
Pynciau:
Brief Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8013903/
https://ncbi.nlm.nih.gov/pubmed/33511686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/joim.13231
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg